ArriVent BioPharma Inc. Common Stock (AVBP)
Stock · NASDAQ · Health Care
$30.17as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support Confirmation90.2%
High Beta25.1%
Support level
$29.9
Industry
Biotechnology: Pharmaceutical Preparations
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-sm…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 77
- Website
- arrivent.com/
Fundamentals
- 1-day range
- $29.75$31.37
- Market cap
- $1.38B
- P/E (trailing)
- —
- P/E (forward)
- -7.93
- EPS (trailing)
- $-3.52
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 554.4K
52-week range
$17$35.83
Next earnings: November 16, 2026 · EPS estimate $-1.07confirmed
Forecasts
10 analyst ratings
Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$50
+65.7%
Median
$45
+49.2%
Low
$40
+32.6%
ArriVent BioPharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AVBPArriVent BioPharma Inc. Common Stock$30.19▼ 2.63%Market cap $1.38BP/E —$17$35.83
- XNCRXencor Inc. Common Stock$26.06▼ 9.76%Market cap $1.44BP/E —$7.8$30.61
- HROWHarrow Inc. Common Stock$37.23▼ 3.40%Market cap $1.46BP/E —$28.54$54.85
- PAHCPhibro Animal Health Corporation Class A Common Stock$37.64▲ 3.55%Market cap $1.51BP/E 14.51$28.25$60.08
- ETONEton Pharmaceuticals Inc. Common Stock$59.79▼ 4.60%Market cap $1.24BP/E 150.92$14.27$66.37
- ARDXArdelyx Inc. Common Stock$3.81▼ 0.26%Market cap $1.23BP/E —$3.73$8.4
- LBRXLB Pharmaceuticals Inc Common Stock$47.8▼ 0.20%Market cap $1.23BP/E —$13.36$50.16
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVBP ArriVent BioPharma Inc. Common Stock | $1.38B | — | $30.19 | ▼ 2.63% | $17$35.83 |
| XNCR Xencor Inc. Common Stock | $1.44B | — | $26.06 | ▼ 9.76% | $7.8$30.61 |
| HROW Harrow Inc. Common Stock | $1.46B | — | $37.23 | ▼ 3.40% | $28.54$54.85 |
| PAHC Phibro Animal Health Corporation Class A Common Stock | $1.51B | 14.51 | $37.64 | ▲ 3.55% | $28.25$60.08 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.24B | 150.92 | $59.79 | ▼ 4.60% | $14.27$66.37 |
| ARDX Ardelyx Inc. Common Stock | $1.23B | — | $3.81 | ▼ 0.26% | $3.73$8.4 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.23B | — | $47.8 | ▼ 0.20% | $13.36$50.16 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside CaseSeekingAlpha · 8/27/2026
- Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · 8/17/2026
- HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47Benzinga · 8/17/2026
- Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40Benzinga · 8/13/2026
- Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price TargetBenzinga · 8/13/2026
- BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price TargetBenzinga · 8/13/2026
- ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) EstimateBenzinga · 8/12/2026
Insider Activity
Insider Actions →Acquired
54.2K
Disposed
0
- Parsey Merdad · June 18, 2026 · Grant13.6K
- Nolet Chris · June 18, 2026 · Grant13.6K
- Hohneker John · June 18, 2026 · Grant13.6K
- Peterson Kristine · June 18, 2026 · Grant13.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 42.06M
- Total value held
- $966.29M
- Institutional holders
- 133
Top holders this quarter
- Unknown4.40M
- Unknown4.15M
- Unknown3.93M
- Unknown3.03M
- Unknown3.02M
- Unknown2.53M
- Unknown1.97M
- Unknown1.94M
- Unknown1.70M
- Unknown1.53M
See the full, filterable feed with live charts on the MarketWall dashboard.